All News

Perirenal hematoma characteristics determined by computed tomography may be suggestive of the need for angiographic embolization in patients who present with blunt renal trauma, a study from the University of Texas Southwestern Medical Center, Dallas, suggests.

Urology Times asked urologists around the country whether the ability of a dissatisfied patient to broadcast his discontent on the Internet has changed the way they deal with those patients and whether additional measures are needed to prevent those patients from trashing a physician's reputation online.

Rising temperatures associated with global warming may be accompanied by a significant, costly increase in the incidence of kidney stones. Climate change may increase stone incidence rates by up to 30% in some regions.

A small percentage of males born with cryptorchidism are more likely to have genetic mutations, including those for a syndrome that is a common genetic cause of infertility, according to a study by Italian researchers.

A new report from the nation's leading cancer organizations shows that, for the first time since the report was first issued in 1998, both incidence and death rates for all cancers combined are decreasing for both men and women, driven largely by declines in prostate, breast, and other common cancers.

Selenium may aid in the prevention of high-risk bladder cancer, according to a study by researchers from Dartmouth Medical School, Lebanon, NH. The news follows a less-encouraging report from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showing that supplementation with selenium or vitamin E was not associated with a lower risk of prostate cancer.

The FDA has accepted the new drug application for a 6-month formulation of triptorelin pamoate (Trelstar), a luteinizing hormone releasing hormone agonist for the palliative treatment of advanced prostate cancer, according to Watson Pharmaceuticals, the drug's manufacturer.

A European phase III double-blind placebo controlled study of PSD502, a proprietary formulation of lidocaine and prilocaine for the treatment of premature ejaculation, has met its three co-primary endpoints of intra-vaginal ejaculation latency time (IELT) and index of premature ejaculation (IPE), Plethora Solutions Holdings PLC has announced.